Lito Sousa

I mean, it's all you can do.

He was clearly talking about spinning company, wasn't he? I don't know, Lito.

I don't know.

So outside the clip, if you watch the whole week interview, someone asks him about like the sides of this media beef and that they're tired of it.

Okay.

jesus christ uh the whole timeline of the agreement is a joke anyway i do not disagree with you barry i don't know why you have to behave for two months leading up to the games and not all year to to get that agreement right i don't know

where's where's the window open and where's it closed Because Lito's got a great point right here.

Lito says, my question is, when is the cutoff point you can criticize Dave? Mason said he was washed a while ago, but that was okay.

It's

gone! Yeah, baby! Needs a pass to Lito! Stopped by Lito! The roll! Scores! Johnny Gattrell wins it! Hello

and welcome to Talking Flames, your favorite hockey podcast covering everything you need to know about your Calgary Flames.

I am your host, Ryan Hunt.

Thanks for listening, and don't forget to follow and rate us in your podcast app.

This is the fourth article in our series on Creutzfeldt-Jakob disease, a series that began in August 2026 as a dedication to Lito Sousa, the Brazilian aviation communicator who made his diagnosis public.

Every episode so far has followed one idea, lower the prion protein, silence the gene, cut the RNA, starve the disease of the raw material it needs.

Today, we leave that road entirely.

Obrigada por ouvir e não esqueça de seguir e avaliar o programa no seu aplicativo de podcast.

Em agosto de 2026, a gente publicou dois episódios dedicados ao Lito Sousa, o comunicador de aviação por trás do canal Aviões e Músicas, que tornou público o diagnóstico de doença de Creutzfeldt-Jakob.

A gente disse na época que eram dois episódios.

A gente errou.

Thanks for listening, and don't forget to follow and rate us in your podcast app.

In August 2026, we published two episodes dedicated to Lito Sousa, the Brazilian aviation communicator behind the channel Aviões e Músicas, Airplanes and Music, who shared publicly that he had been diagnosed with Creutzfeldt-Jakob disease.

We said then that there were two episodes.

We were wrong.

Uhum!

Este é o segundo de dois episódios dedicados ao Lito Souza, o comunicador de aviação por trás do canal Aviões e Músicas, que tornou público em agosto de 2026, o diagnóstico de doença de Creutzfeldt-Jakob.

No episódio anterior, a gente olhou pra uma abordagem de silenciamento genético que tá entrando agora no primeiro teste em humanos.

Hoje a gente volta ao estudo que abriu esse campo inteiro, o experimento que mostrou pela primeira vez, em animais vivos, que reduzir a proteína priônica depois que os sintomas já começaram, ainda pode mudar o curso da doença.

Não tem histórico familiar, não tem aviso prévio, não tem um teste de rotina cinco anos antes.

É aleatório.

O próprio Lito Souza relatou justamente como esse diagnóstico despenca do nada na sua vida.

A pessoa tá vivendo normal e de repente o relógio começa a correr rápido demais.

Yes, thank you for tuning in.

This is the second of two episodes dedicated to Lito Sousa, the Brazilian aviation communicator behind the channel Aviões e Músicas, Airplanes and Music, who shared publicly in August 2026 that he had been diagnosed with Creutzfeldt-Jakob disease.

In our previous episode, we looked at a genetic silencing approach now entering its first human trial.

Today, we go back to the study that opened this whole field, the experiment that first showed in living animals that lowering prion protein after symptoms have already begun can still change the course of the disease.

If we can engineer a sequence-specific molecular interceptor to turn off a single protein, if we can halt one of the most aggressive, untreatable, fatal brain diseases simply by starving it of its genetic fuel, what other fatal, untreatable diseases hiding in our DNA are just waiting for the right RNA switch to be flipped off?

It's the exact question driving the bleeding edge of genomic medicine today.

We close this pair of episodes where we began, with Lito Sousa.

To the investigators and sponsors running prion disease trials at Ionis, at the Broad Institute, and at the centers collaborating with them, there is a patient in Brazil on a waiting list and a community following your work with real attention.